168 related articles for article (PubMed ID: 6628500)
21. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
Norman TR; Burrows GD
Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
[TBL] [Abstract][Full Text] [Related]
22. Interaction between moclobemide and oral tyramine in depressed patients.
Burgess CD; Mellsop GW
Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
[TBL] [Abstract][Full Text] [Related]
23. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial.
Larsen JK; Holm P; Mikkelsen PL
Acta Psychiatr Scand; 1984 Sep; 70(3):254-60. PubMed ID: 6388247
[TBL] [Abstract][Full Text] [Related]
24. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
Gieschke R; Schmid-Burgk W; Amrein R
J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
[TBL] [Abstract][Full Text] [Related]
25. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491.
Keller HH; Kettler R; Keller G; Da Prada M
Naunyn Schmiedebergs Arch Pharmacol; 1987 Jan; 335(1):12-20. PubMed ID: 3574489
[TBL] [Abstract][Full Text] [Related]
26. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
Nair NP; Ahmed SK; Kin NM
J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
[TBL] [Abstract][Full Text] [Related]
27. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
Bergström M; Westerberg G; Németh G; Traut M; Gross G; Greger G; Müller-Peltzer H; Safer A; Eckernäs SA; Grahnér A; Långström B
Eur J Clin Pharmacol; 1997; 52(2):121-8. PubMed ID: 9174681
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology of reversible MAO-A inhibitors.
Bieck PR; Antonin KH; Schmidt E
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():345A-346A. PubMed ID: 1498864
[No Abstract] [Full Text] [Related]
29. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.
Scheinin M; Koulu M; Karhuvaara S; Zimmer RH
Life Sci; 1990; 47(16):1491-9. PubMed ID: 2250565
[TBL] [Abstract][Full Text] [Related]
30. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes.
Coupland NJ; Wilson SJ; Potokar JP; Bell CE; Bailey JE; Nutt DJ
Int Clin Psychopharmacol; 1995 Nov; 10(4):229-38. PubMed ID: 8748044
[TBL] [Abstract][Full Text] [Related]
32. An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration.
Rafii H; Chalon S; Ombetta JE; Frangin Y; Pourcelot L; Besnard JC; Bodard S; Guilloteau D
Life Sci; 1996; 58(14):1159-69. PubMed ID: 8614267
[TBL] [Abstract][Full Text] [Related]
33. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
Laux G; Beckmann H; Classen W; Becker T
J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241
[TBL] [Abstract][Full Text] [Related]
34. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
[TBL] [Abstract][Full Text] [Related]
35. [Moclobemide (Aurorix), the first MAO-A-inhibitor: really something new?].
Nolen WA; Birkenhäger TK; Moleman P
Ned Tijdschr Geneeskd; 1992 Aug; 136(31):1492-6. PubMed ID: 1495565
[No Abstract] [Full Text] [Related]
36. Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
Stefanis CN; Alevizos BH; Papadimitriou GN
Int Pharmacopsychiatry; 1982; 17(1):43-8. PubMed ID: 7045018
[TBL] [Abstract][Full Text] [Related]
37. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.
Da Prada M; Kettler R; Keller HH; Cesura AM; Richards JG; Saura Marti J; Muggli-Maniglio D; Wyss PC; Kyburz E; Imhof R
J Neural Transm Suppl; 1990; 29():279-92. PubMed ID: 2193111
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
[TBL] [Abstract][Full Text] [Related]
39. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
Dingemanse J; Korn A; Pfefen JP; Güntert TW
Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
[TBL] [Abstract][Full Text] [Related]
40. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies.
Delini-Stula A; Baier D; Kohnen R; Laux G; Philipp M; Scholz HJ
Pharmacopsychiatry; 1999 Mar; 32(2):61-7. PubMed ID: 10333164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
